NextCure, Inc.
NMS: NXTCLive Quote
📈 ZcoreAI Score
Our AI model analyzes NextCure, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NXTC Z-Score →About NextCure, Inc.
Healthcare
Biotechnology
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
📊 Fundamental Analysis
NextCure, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -111.2%, which indicates that capital utilization is currently under pressure.
At a current price of $11.64, NXTC currently sits at the 67th percentile of its 52-week range (Range: $3.49 - $15.74).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$41.44M
Trailing P/E
--
Forward P/E
-1.84
Beta (5Y)
1.58
52W High
$15.74
52W Low
$3.49
Avg Volume
37K
Day High
Day Low